Literature DB >> 30766550

Impact of weight reduction on insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients.

Shehab M Abd El-Kader1, Osama H Al-Jiffri2.   

Abstract

BACKGROUND: Type 2 diabetes mellitus is usually related to vascular problems and is associated with impairment in endothelial function characterized by impaired endothelial-dependent vasodilation and increased platelet adhesion. There is limitation in clinical studies that have addressed the beneficial effects of weight reduction in modulating biomarkers of endothelial dysfunction and adipokines dysregulation for obesity associated with type 2 diabetes mellitus.
OBJECTIVE: This study was designed to detect the effects of weight loss on insulin resistance, adhesive molecules and adipokines dysregulation in obese type 2 diabetic patients.
METHODS: Eighty obese patients with type 2 diabetes mellitus, their age ranged from 35-55 years and their body mass index ranged from 31-37 kg/m2 were equally assigned into 2 groups: the weight reduction group received aerobic exercises in addition to diet regimen, where the control group received medical treatment only for 12 weeks.
RESULTS: There was a 24.04%, 19.33%, 22.78% ,12.28%, 9.35%, 22.53% & 10.12 % reduction in mean values of Homeostasis Model Assessment-Insulin Resistance Index (HOMA-IR), Leptin, Adiponectin, Resistin, intercellular cell adhesion molecule -1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin & body mass index (BMI) respectively in addition to 26.20% & 24.58% increase in the mean values of adiponectin & the quantitative insulin-sensitivity check index (QUICKI) respectively in group (A) at the end of the study. The mean values of leptin, resistin, insulin, HOMA-IR, ICAM-1, VCAM-1, E-selectin & BMI were significantly decreased in addition to significant increase in the mean values of adiponectin & QUICKI in group (A) those that received aerobic exercise training in addition to diet regimen. While the results of group (B) those that received no treatment intervention were not significant. In addition, there were significant differences between mean levels of the investigated parameters in group (A) and group (B) after treatment (P<0.05).
CONCLUSION: Within the limit of this study, 10% reduction in body mass index modulates insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients.

Entities:  

Keywords:  Type 2 Diabetes; adhesive molecules; adipokines; insulin resistance; obesity; weight reduction

Mesh:

Substances:

Year:  2018        PMID: 30766550      PMCID: PMC6354881          DOI: 10.4314/ahs.v18i4.5

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


Introduction

Type 2 diabetes (T2DM) is an important cardiovascular (CV) risk factor1. Obesity represents a state of increase in adipose tissue mass due to the increase in the number and size of adipocytes2. Diabetes increases cardiovascular risk and reduces life expectancy, with most of excess mortality being attributable to cardiovascular causes3. In addition, T2DM is typically associated with reduced high density lipoprotein cholesterol (HDL-C) and impaired HDL-C function4,5. The hypertension that typically accompanies T2DM seems to be the most significant contributor to this increased risk6. Adipose tissue is recognized as an active endocrine organ, which secretes adipocytokines involved in the local and systemic regulation of numerous metabolic and inflammatory processes7. Dysregulated endocrine function of the adipose tissue contributes to the development of obesity related metabolic disorders including insulin resistance, T2DM and atherosclerosis8. Adiponectin is an adipokine with insulin sensitizing and anti-inflammatory activities. Adiponectin and insulin resistance is an important link between visceral adiposity and atherosclerosis. Adiponectin improves systemic glucose tolerance and protects the vasculature from atherosclerosis9. Adiponectin exerts both vasodilatory and insulin-sensitizing actions and its levels are decreased in insulin-resistant humans and animals10. Circulating levels of adiponectin decrease both in obesity and in patients with T2DM. There is a close association between inflammatory markers, insulin resistance and incidence of T2DM11. Additionally, hypoadiponectinemia is an independent risk factor for developing T2DM and cardiovascular disease12. Type 2 diabetic patients have abnormal levels of inflammatory markers, which lead to endothelial cell dysfunction13, which may be induced by hyperlipidemia, hyperinsulinemia and pancreatic β-cell failure14. Insulin has an essential role in regulation of vascular function by stimulation of the expression of vascular cell adhesion molecule (vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule -1 (ICAM-1) and E-selectin on endothelium, that is why endothelial dysfunction is associated with insulin resistance15. Endothelial dysfunction is characterized by prothrombic properties, pro-inflammatory state and reduced vasodilation16,17. Endothelial function is a marker of overall cardiovascular health and a predictor of future cardiovascular events18. Aerobic exercises associated with appropriate diet regimen were reported to protect against atherosclerosis in non-insulin dependent diabetes mellitus19. However, weight reduction program modulates markers of systemic inflammation, endothelial function and adipokines that are usually associated with better cardiovascular system prognosis in obese subjects20,21. As there is inconclusive data regarding the impact of weight reduction upon the adipokines and adhesive molecules dysregulation in obese type 2 diabetic patients, therefore, the study aimed to determine the impact of 12 weeks of weight reduction program on insulin resistance, adipokines and adhesive molecules dysregulation in obese type 2 diabetic patients.

Patients and methods

Subjects

Eighty obese T2DM patients (48 males and 32 females) with body mass index (BMI) ranged from 30 to 34 Kg/m2, treated with oral hypoglycemic agents e.g. metformin and/or pioglitazone were selected for the study on referral to Internal Medicine Department, King Abdulaziz University Teaching Hospital, Saudi Arabia. They were checked for fasting/random glucose levels. Only participants who had fasting blood sugar levels more than 5.6 mmol/l or random blood sugar level more than 7.8 mmol/l (impaired blood sugar) were included in this study and were further checked for type 2 diabetes mellitus as per recent American Diabetes Association criteria i.e. fasting blood sugar ≥7.0 mmol/l or post-prandial blood sugar ≥11.1 mmol/l 2-h plasma glucose 11.1 mmol/l during an oral glucose tolerance test and glycosylated hemoglobin (HbA1c%) > 6.5%22. Exclusion criteria included smokers, kidney insufficiency, congestive heart failure, pregnant female patients, hepatitis and respiratory failure. Detailed clinical history was obtained and p included the age, sex, symptoms suggestive of diabetes and family history of diabetes. Physical examinations included anthropometric measurements such as height, weight, BMI and waist circumference. Participants were included two groups; group (A) received treadmill aerobic exercise training on treadmill in addition to diet regimen. However, group (B) received no exercise training. The CONSORT diagram outlining the details of the screening, run-in and randomization phases of the study and reasons for participant exclusion can be found in figure (1). Informed consent was obtained from all participants. This study was approved by the Scientific Research Ethical Committee, Faculty of Applied Medical Sciences at King Abdulaziz University.
Figure 1

Measurements

All laboratory examinations were performed at Laboratory of King Abdalaziz University Teaching Hospitals. A. Measurement of adiopkines and insulin resistance: After a 10 hours overnight fast, venous blood samples were drawn to determine levels of leptin, adiponectin and resistin. Serum level of leptin was measured with DRG leptin ELISA Catalog number EIA-2395, supplied by DRG instruments GmbH, Germany and serum level of adiponectin was determined using AviBion human adiponectin (Acrp 30) ELISA kit ref. no. ADIPO 25 (Orgenium Laboratories, Finland), while serum level of resistin was measured by ELISA using commercially available kits (resistin Rapidbio, West Hills, CA, USA; CK-18: PEVIVA, Alexis, Grunwald, Germany) according to the manufacturer's instructions. Human insulin was measured with an insulin kit (Roche Diagnostics, Indianapolis, IN, USA) using a cobas immunoassay analyzer(Roche Diagnostics). Insulin resistance was assessed by homeostasis model assessment (HOMA-IR). HOMA-IR = fasting blood glucose (mmol/l) _ fasting insulin (mIU/ml)/22.523. However, insulin sensitivity was assessed by The quantitative insulin-sensitivity check index (QUICKI) using the formula: QUICKI=1/log(insulin) + log(glucose)24. All serum samples were analyzed in duplicates. B. Measurement of adhesive molecules biomarkers: Biomarkers of adhesive molecules which included adhesion molecules (ICAM-1 and VCAM-1) and soluble E-selectin levels were measured from frozen plasma samples stored at −80 °C. Enzyme-linked immunosorbent assays kits (ELISAs) were used to measure soluble levels of ICAM-1, VCAM-1 and sE-selectin (GE Healthcare Amersham, Biotrak Easy ELISA), which employs the quantitative sandwich enzyme immunoassay technique. C. Measurement of anthropometric parameters: Body weight of all participants was measured with (HC4211, Cas Korea, South Korea) while wearing hospital gowns and undergarments. Where the height was measured with a digital stadiometer (JENIX DS 102, Dongsang), so Body Mass Index (BMI) was computed as BMI= Body weight/Height2.

Procedures

All participants were divided randomly into the following groups: 1. Group (A): Forty obese type 2 diabetic patients were submitted to the aerobic exercise training to complete a 12-week aerobic exercise on a treadmill which was conducted according to recommendation of American College of Sports Medicine regarding aerobic exercise application25. Training program included 5 minutes for warming -up in the form of range motion and stretching exercises, 30 minutes of aerobic exercise training ( 60–70% of maximum heart rate) and 10 minutes of cooling down ( on treadmill with low speed and without inclination). Participants had 3 sessions /week for 3 months with close supervision of physical therapist. In addition, a dietician performed an interview-based food survey for all participants of group (A) for detection of feeding habits, abnormal dietary behavior and to prescribe the balanced low caloric diet that provides 1200 Kilocalories/day for 12 weeks. 2. Group (B): Forty obese type 2 diabetic patients of both sexes maintained their ordinary life style and received no exercise training.

Statistical analysis

The mean values of the investigated parameters obtained before and after three months in both groups were compared using paired “t” test. Independent “t” test was used for the comparison between the two groups (P<0.05).

Results

Eighty obese patients with type 2 diabetes mellitus completed the screening evaluation. The baseline characteristics of the participants are shown in table (1). Most participants (60%) were men. Forty participants were assigned group (A) (n = 40; 23 males and 16 females) and group (B) (n =40, 25 males and 15 females). None of the baseline characteristics differed significantly between the two groups as listed in table (1).
Table (1)

Mean value of baseline characteristics of subjects for participants in both groups

Group (A)Group (B)Significance
Age (year)48.73 ± 6.2650.12 ± 5.91P>0.05
Gender (male/female)23/1725/15P>0.05
BMI (kg/m2)32.51 ± 3.8733.14 ± 3.22P>0.05
Duration of diabetes (years)12.23 ± 4.6411.52 ± 4.58P>0.05
Waist circumference (cm)103.42 ± 8.36101.47 ± 7.93P>0.05
Waist-hip ratio0.97 ± 0.080.93 ± 0.07P>0.05
Body fat (%)36.4 ± 7.6135.88 ± 6.95P>0.05
SBP (mmHg)143.57 ± 10.31145.41 ± 9.86P>0.05
DBP (mmHg)87.44 ± 7.1588.69 ± 8.21P>0.05
Total Cholesterol (mg/dL)199.72± 21.63196.94 ± 19.54P>0.05
HDL-C (mg/dL)43.81 ± 8.4546.17 ± 9.38P>0.05
Triglycerides (mg/dL)145.64 ± 13.87142.33 ± 14.56P>0.05
HBA1c (%)9.17 ± 2.538.92 ± 2.65P>0.05
Glucose (mmol/L)5.32 ± 1.135.18 ± 1.08P>0.05
Insulin (pmol/L)21.49 ± 4.7619.98 ± 5.14P>0.05

BMI: Body Mass Index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; HDL-C: High-density lipoprotein cholesterol; HBA1c: glycosylated hemoglobin.

Mean value of baseline characteristics of subjects for participants in both groups BMI: Body Mass Index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; HDL-C: High-density lipoprotein cholesterol; HBA1c: glycosylated hemoglobin. There was a 24.04%, 19.33%, 22.78% ,12.28%, 9.35%, 22.53% & 10.12 % reduction in mean values of HOMA-IR, Leptin, Adiponectin, Resistin, ICAM-1, VCAM-1 and E-selectin & BMI respectively in addition to 26.20% & 24.58% increase in the mean values of adiponectin & QUICKI respectively in group (A) at the end of the study. The mean values of leptin, resistin, insulin, HOMA-IR, ICAM-1, VCAM-1, E-selectin & BMI were significantly decreased in addition to significant increase in the mean values of adiponectin & QUICKI in group (A) those that received aerobic exercise training in addition to diet regimen. While the results of group (B) who received no treatment intervention were not significant. Also, there were significant differences between mean levels of the investigated parameters in group (A) and group (B) after treatment (Table 2, 3, & 4) (P<0.05).
Table (2)

Mean value and significance of BMI, QUICKI, HOMA-IR, Leptin, Adiponectin, Resistin, ICAM-1, VCAM-1 and E-selectin in group (A) before and after treatment

Mean +SDT-valueSignificance
PrePost
BMI (kg/m2)32.51 ± 3.87*29.22 ± 3.746.73P<0.05
QUICKI0.118 ± 0.019*0.147 ± 0.0155.12P <0.05
HOMA-IR5.24 ± 1.57*3.98 ± 1.314.67P <0.05
Leptin (Ng/ml)30.21 ± 4.32*24.37 ± 3.916.32P<0.05
Adiponectin (µg/mL)10.42 ± 2.65*13.15 ± 2.485.74P<0.05
Resistin (ng/mL)15.23± 2.87*11.76 ± 2.226.21P <0.05
ICAM-1 (ng/ml)92.71 ± 9.36*81.32 ± 8.177.56P<0.05
VCAM-1 (ng /ml)816.58 ± 28.15*740.26 ± 21.839.81P<0.05
E-selectin (ng/ml)15.93 ± 2.76*12.34 ± 2.547.56P<0.05

BMI: Body Mass Index; QUICKI: The quantitative insulin-sensitivity check index; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance Index; ICAM-1: Inter-Cellular Adhesion Molecule; VCAM-1: Vascular Cell Adhesion Molecule;

indicates a significant difference, P < 0.05

Table (3)

Mean value and significance of BMI, QUICKI, HOMA-IR, Leptin, Adiponectin, Resistin, ICAM-1, VCAM-1 and E-selectin in group (B) before and after treatment

Mean +SDT-valueSignificance
PrePost
BMI (kg/m2)33.14 ± 3.2233.85 ± 3.231.19P>0.05
QUICKI0.121 ± 0.0240.115 ± 0.0180.87P > 0.05
HOMA-IR5.63 ± 2.135.97 ± 2.241.26P > 0.05
Leptin(Ng/ml)31.36 ± 4.1631.68 ± 4.511.40P>0.05
Adiponectin(µg/mL)10.15 ± 2.329.87 ± 2.170.86P <0.05
Resistin (ng/mL)16.11 ± 2.5316.34 ± 2.181.21P > 0.05
ICAM-1(ng/ml)93.19 ± 10.2294.50 ± 9.831.58P>0.05
VCAM-1 (ng /ml)820.21 ± 26.75826.10± 29.211.89P>0.05
E-selectin(ng/ml)16.14 ± 2.5016.62 ± 2.650.84P>0.05

BMI: Body Mass Index; QUICKI: The quantitative insulin-sensitivity check index; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance Index; ICAM-1: Inter-Cellular Adhesion Molecule; VCAM-1: Vascular Cell Adhesion Molecule.

Table (4)

Mean value and significance of BMI, QUICKI, HOMA-IR, Leptin, Adiponectin, Resistin, ICAM-1, VCAM-1 and E-selectin in group (A) and group (B) at the end of the study

Mean +SDT-valueSignificance
Group (A)Group (B)
BMI (kg/m2)29.22 ± 3.74*33.85 ± 3.235.23P <0.05
QUICKI0.147 ± 0.015*0.115 ± 0.0184.10P <0.05
HOMA-IR3.98± 1.31*5.97 ± 2.243.83P <0.05
Leptin(Ng/ml)24.37 ± 3.91*31.68 ± 4.515.14P <0.05
Adiponectin(µg/mL)13.15 ± 2.48*9.87 ± 2.174.32P <0.05
Resistin (ng/mL)11.76 ± 2.22*16.34 ± 2.185.12P <0.05
ICAM-1(ng/ml)81.32 ± 8.17*94.50 ± 9.836.43P <0.05
VCAM-1 (ng /ml)740.26 ± 21.83*826.10± 29.218.26P <0.05
E-selectin(ng/ml)12.34 ± 2.54*16.62 ± 2.656.27P <0.05

BMI: Body Mass Index; QUICKI: The quantitative insulin-sensitivity check index; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance Index; ICAM-1: Inter-Cellular Adhesion Molecule; VCAM-1: Vascular Cell Adhesion Molecule;

indicates a significant difference, P < 0.05

Mean value and significance of BMI, QUICKI, HOMA-IR, Leptin, Adiponectin, Resistin, ICAM-1, VCAM-1 and E-selectin in group (A) before and after treatment BMI: Body Mass Index; QUICKI: The quantitative insulin-sensitivity check index; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance Index; ICAM-1: Inter-Cellular Adhesion Molecule; VCAM-1: Vascular Cell Adhesion Molecule; indicates a significant difference, P < 0.05 Mean value and significance of BMI, QUICKI, HOMA-IR, Leptin, Adiponectin, Resistin, ICAM-1, VCAM-1 and E-selectin in group (B) before and after treatment BMI: Body Mass Index; QUICKI: The quantitative insulin-sensitivity check index; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance Index; ICAM-1: Inter-Cellular Adhesion Molecule; VCAM-1: Vascular Cell Adhesion Molecule. Mean value and significance of BMI, QUICKI, HOMA-IR, Leptin, Adiponectin, Resistin, ICAM-1, VCAM-1 and E-selectin in group (A) and group (B) at the end of the study BMI: Body Mass Index; QUICKI: The quantitative insulin-sensitivity check index; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance Index; ICAM-1: Inter-Cellular Adhesion Molecule; VCAM-1: Vascular Cell Adhesion Molecule; indicates a significant difference, P < 0.05

Discussion

Type 2 diabetes mellitus is characterized by hyperglycemia due to insulin resistance, which over time leads to a myriad of micro- and macrovascular complications. Individuals with T2DM are at a much higher risk (two to four times that of the background population) of developing coronary artery disease26, peripheral vascular disease27, and cerebrovascular disease28. Mortality from cardiovascular disease may be up to four times higher in patients with T2DM29. However, adiponectin is a circulating adipose tissue-derived hormone that is down regulated in obese individuals30. Experimental studies show that adiponectin plays a protective role in the development of insulin resistance, atherosclerosis, and inflammation31. Insulin resistance and its manifestations predict and precede T2DM and its cardiovascular complications32. Insulin resistance characterizing obese subjects has also been shown to be associated with endothelial dysfunction33,34. The optimal management of obesity starts with a combination of diet, physical activity, and behavioral modification. Previous studies demonstrated beneficial effects of exercise training and caloric restrictions on pro-inflammatory state associated with endothelial dysfunction after weight loss35–37. The main finding of the present study was that weight reducing program ameliorate insulin resistance, adhesive molecules (ICAM-1 VCAM-1 and E-selectin) as well as improvement in adipokines dysregulation (Adiponectin, Leptin and Resistin) in obese type 2 diabetic patients as a result of weight loss, these results are in line with many previous studies. Regarding insulin resistance, this study proved that life style modification (aerobic exercise and diet regimen) significantly improved insulin resistance because of weight reduction. These results agreed with Angelico et al. who proved that 5%–10% weight loss as a result of diet regimen modulates insulin resistance in patients with metabolic syndrome38, also Bacchi et al. conducted a randomized controlled trial of 31 sedentary adults with type 2 diabetes and non-alcoholic fatty liver comparing the effects of 4 months of aerobic and resistance training on insulin sensitivity and hepatic steatosis. Hepatic fat content, hepatic steatosis and insulin sensitivity were reduced in both intervention groups39. Several mechanisms have been proposed to be responsible for the increases in insulin sensitivity after exercise training. These include increased post-receptor insulin signaling, increased glucose transporter protein and mRNA, increased activity of glycogen syntheses and hexokinase, decreased release and increased clearance of free fatty acids, increased muscle glucose delivery and changes in muscle composition40. Concerning adhesive molecules, this study proved that life style modification (aerobic exercise and diet regimen) significantly improved ICAM-1, VCAM-1 and E-selectin because of weight reduction. These results agreed with previous studies conducted in obese populations that have shown reductions in VCAM-141 and ICAM-142–44 following weight loss. Sharman and Volek conducted a 6-week crossover dietary intervention with reduced energy diets (low fat vs very low carbohydrate ∼1500 kcal) in 15 overweight men, resulted in reduction in plasma ICAM-145. Forsythe et al. conducted a parallel study with longer period dietary intervention (12-week) in a group of overweight individuals with dyslipidemia and stated that weight reduction was achieved which led to reduction in E-selectin and ICAM46. Thomson et al. conducted a study on 50 overweight/obese women with polycystic ovary syndrome to determine if 20 weeks of a high-protein energy-restricted diet with or without exercise in women with polycystic ovary syndrome could improve endothelial function. Participants were randomly assigned by computer generation to one of three 20-week interventions: diet only (6000 kJ/day), diet and aerobic exercise (6000 kJ/day and 5 walking sessions/week) and diet and combined aerobic-resistance exercise (6000 kJ/day, three walking and two-strength sessions/week). All three treatments resulted in significant weight loss, also VCAM-1 and ICAM-1 levels decreased with weight loss with no differences between treatments47. Garanty-Bogacka et al. applied a study on fifty six obese adolescents, participating in an obesity intervention program, were studied before and after 1 year program consisting of moderate physical activity (exercise group including 37 participants) or hypocaloric diet (diet group: 19 subjects) and concluded that moderate-intensity training alone reduced cell adhesion (VCAM-1 and ICAM-1) in obese adolescents more than observed after caloric restriction48. The mechanisms of adhesive molecules improvement are not clearly elucidated, but some studies suggest that reduction in circulating level of markers of endothelial activation and oxidative stress49,50 as well as increases in nitrous oxide bioavailability through repetitive increase of shear stress may serve as mechanisms51,52. Regarding adipokines levels, this study proved that life style modification (aerobic exercise and diet regimen) significantly modulated adipokines (Adiponectin, Leptin and Resistin) because of weight reduction. These results agreed with Lang et al. investigated the effects of an 8-week weight-control program on serum adiponectin and blood lipid level profiles in 3 obese men and 11 obese women, their findings suggest that weight reduction has anti-inflammatory and anti-atherogenic effects via increased serum adiponectin levels53. Esposito et al. reported that lifestyle modification by obese subjects for a period of 2 years led to decreased body weight and C-reactive protein but increased adiponectin levels54 as adiponectin secretion may be inhibited by obesity through a feedback loop55. Rokling-Andersen et al. examined the separate and combined effects of a one year exercise and diet intervention on several adipokines and concluded that beyond the effects on body fatness, diet or exercise intervention alone or in combination mainly had effects on adiponectin and tumor necrosis factor- alpha (TNF-α) concentrations56. In addition, previous studies demonstrated that long-term weight loss after bariatric surgery is accompanied by a decreased pro-inflammatory state and increased the circulating level of adiponectin57–61. Jung et al. proved that long-term exercise program and a diet led obese individuals to reduce significantly the level of resistin and leptin62. Jones et al. have studied the effect of 8-week aerobic exercise on lipid levels of serum, leptin, adiponectin, and resistin in overweight adolescents and reported a significant decrease of resistin63. Kadoglou et al. studied the effect of 16-week regular aerobic exercises with a maximal oxygen consumption (VO2max) of 50 to 85 percent on resistin level in patients with type 2 diabetic and overweight ones. They reported a significant decrease in resistin level among the participants64. In the study by Elloumi et al. two months of exercise with weight loss, led to a significant decrease in resistin level among obese adolescents65. Balducci et al. reported that 12 months of regular physical activity could decrease the level of resistin in patients with diabetes and obesity66. The current study has important strengths and limitations. The major strength is the supervised nature of the study. Supervising physical activity and diet regimen remove the need to question compliance or to rely on activity questionnaires. Further, all exercise sessions were supervised and adherence to the activities was essentially 100%. In addition, our study had a large number of subjects enrolled/involved, leading to excellent statistical power to detect exercise exposure effects across groups. Moreover, the study was randomized; hence, we can extrapolate adherence to the general population. On the other hand, the major limitations is that this study did not include some biomarkers that could be modulated with weight reduction among patients with T2DM. Finally, within the limit of this study, 10% reduction in body mass index modulates insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients. Further researches are needed to explore the impact of different exercise training techniques on quality of life and other biochemical parameters among patients with type 2 diabetes mellitus.
  63 in total

Review 1.  The clinical implications of endothelial dysfunction.

Authors:  Michael E Widlansky; Noyan Gokce; John F Keaney; Joseph A Vita
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

2.  Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.

Authors:  Katherine Esposito; Alessandro Pontillo; Carmen Di Palo; Giovanni Giugliano; Mariangela Masella; Raffaele Marfella; Dario Giugliano
Journal:  JAMA       Date:  2003-04-09       Impact factor: 56.272

3.  Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

Authors:  A Katz; S S Nambi; K Mather; A D Baron; D A Follmann; G Sullivan; M J Quon
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

4.  Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention.

Authors:  M Laimer; C F Ebenbichler; S Kaser; A Sandhofer; H Weiss; H Nehoda; F Aigner; J R Patsch
Journal:  Int J Obes Relat Metab Disord       Date:  2002-05

5.  Nonfasting serum glucose and insulin concentrations and the risk of stroke.

Authors:  S G Wannamethee; I J Perry; A G Shaper
Journal:  Stroke       Date:  1999-09       Impact factor: 7.914

6.  Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries.

Authors:  J Al Suwaidi; S T Higano; D R Holmes; R Lennon; A Lerman
Journal:  J Am Coll Cardiol       Date:  2001-05       Impact factor: 24.094

7.  Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome.

Authors:  Osama Hamdy; Sarah Ledbury; Cathy Mullooly; Catherine Jarema; Satoko Porter; Kerry Ovalle; Amr Moussa; Antonella Caselli; A Enrique Caballero; Panayiotis A Economides; Aristidis Veves; Edward S Horton
Journal:  Diabetes Care       Date:  2003-07       Impact factor: 19.112

8.  Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women.

Authors:  A S Ryan; B J Nicklas; D M Berman; D Elahi
Journal:  Int J Obes Relat Metab Disord       Date:  2003-09

9.  Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease.

Authors:  Julia K Wegge; Christian K Roberts; Tung H Ngo; R James Barnard
Journal:  Metabolism       Date:  2004-03       Impact factor: 8.694

10.  Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding.

Authors:  Hafize Uzun; Kagan Zengin; Mustafa Taskin; Seval Aydin; Gönül Simsek; Nuran Dariyerli
Journal:  Obes Surg       Date:  2004-05       Impact factor: 4.129

View more
  4 in total

Review 1.  Lifestyle interventions for the prevention and treatment of hypertension.

Authors:  Pedro L Valenzuela; Pedro Carrera-Bastos; Beatriz G Gálvez; Gema Ruiz-Hurtado; José M Ordovas; Luis M Ruilope; Alejandro Lucia
Journal:  Nat Rev Cardiol       Date:  2020-10-09       Impact factor: 32.419

2.  Reversibility of pancreatic β-cells dysfunction after vitamin D and calcium supplementation: a pilot study in a population of obese and prepubescent North-African children.

Authors:  Meriem Gaddas; Imed Latiri; Raoudha Kebaili; Ilhem Kacem; Nesrine Jaballah; Jihene Maatoug; Mohamed Salaani; Lamia Boughammoura; Helmi Ben Saad
Journal:  Libyan J Med       Date:  2022-12       Impact factor: 1.657

3.  Methotrexate and Adalimumab Decrease the Serum Levels of Cardiovascular Disease Biomarkers (VCAM-1 and E-Selectin) in Plaque Psoriasis.

Authors:  Natalia Zdanowska; Agnieszka Owczarczyk-Saczonek; Joanna Czerwińska; Jacek J Nowakowski; Anna Kozera-Żywczyk; Witold Owczarek; Wojciech Zdanowski; Waldemar Placek
Journal:  Medicina (Kaunas)       Date:  2020-09-15       Impact factor: 2.430

4.  Association of cognition with leptin and vascular endothelial growth factor in individuals with type 2 diabetes mellitus.

Authors:  Mark A Espeland; Joni K Evans; Owen Carmichael; Jose A Luchsinger; Santica M Marcovina; Rebecca Neiberg; Karen C Johnson; Steven E Kahn; Kathleen M Hayden
Journal:  Obesity (Silver Spring)       Date:  2022-08-03       Impact factor: 9.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.